Nausea medicine help reduce or treat nausea and vomiting. They act on the parts of the brain that controls these sensations and movements. These medicines are available in oral as well as suppository forms for patients unable to take anything orally.
The global Nausea Medicine Market is estimated to be valued at US$ 2.8 Bn in 2023 and is expected to exhibit a CAGR of 6.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends: Innovation in antiemetic drug development has led to significant improvements in nausea treatment outcomes. Leading pharmaceutical players are investing heavily in developing novel antiemetic medications with better efficacy and reduced side effects. For instance, Takeda Pharmaceutical’s Akynzeo aims to provide dual blockade of 5-HT3 and NK1 receptors to enhance antiemetic effect. Similarly, GlaxoSmithKline’s Zofran offers the advantages of targeting a single receptor to control nausea & vomiting. Such innovation in antiemetic medication development is expected to drive higher uptake of new drugs and thereby fuel growth of the global nausea medicine market during the forecast period.
Strength: Nausea medicines provide quick relief from nausea symptoms. The medicines are easily available over-the-counter in pharmacies and online.
Weakness: Long term usage of anti-nausea medicines can cause side effects like drowsiness and headaches. Some medicines are not suitable for pregnant women.
Opportunity: Growing incidence of nausea due to motion sickness, chemotherapy, and pregnancy provides scope for market growth. Rising awareness about available treatment options will boost demand.
Threats: Alternative therapies like acupuncture and yoga are gaining popularity and affecting sales of medicines. Patent expiry of blockbuster drugs leads to price erosion and competition.
The global nausea medicine market is expected to witness high growth. The market size is forecast to reach US$ 2.8 Bn by 2024, expanding at a CAGR of 6.3% during the forecast period of 2023 to 2030.
North America currently dominates the nausea medicine market, owing to high awareness levels and easy accessibility of advanced drugs. Asia Pacific is expected to witness fastest growth supported by rising healthcare expenditure, large patient pool, and increasing adoption of Western lifestyles in countries like India and China.
Key players operating in the nausea medicine market are GlaxoSmithKline plc., Pfizer Inc., Novartis International AG, Sanofi S.A., Merck & Co., Inc., Johnson & Johnson, Bayer AG, Takeda Pharmaceutical Company Limited, AstraZeneca plc., and Eli Lilly and Company.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it